US FDA, Advisory Committees Rarely Disagree
A Milbank Quarterly study and a Pink Sheet analysis show that disagreement between the US FDA and its advisory committee meetings doesn't happen often; it is even rarer for the agency to approve a drug against the advice from a panel.
You may also be interested in...
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.
There are strong reasons to justify an advisory committee meeting for the NASH application, but also an outlet for the US FDA to skip it.
US FDA's Arthritis Advisory Committee narrowly votes to expand label for BI's nintedanib for treatment of systemic sclerosis associated interstitial lung disease, with panelists split on whether further data on its risk/benefit profile can be gathered post-approval.